RECORD // Company

Benitec Biopharma Inc.

Built 2026-11-22T05:11:30Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Benitec Biopharma, Inc. · Ctgov · same registered legal name as 'Benitec Biopharma Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001193125-26-459383

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-12,925,0003 months ended 2026-09-3010-Q2026-11-130001193125-26-4593832026-11-22 05:11 UTCReport an error
Cash and cash equivalents$176,368,000at 2026-09-3010-Q2026-11-130001193125-26-4593832026-11-22 05:11 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001808898
Ticker
BNTC
Record ID
sx:sec:0001808898

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

23 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-13SEC EDGAR company profile2026-11-22 05:11 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-13SEC EDGAR company profile2026-11-22 05:11 UTCReport an error
State of incorporationDE2026-11-13SEC EDGAR company profile2026-11-22 05:11 UTCReport an error
Fiscal year end (MMDD)12312026-11-13SEC EDGAR company profile2026-11-22 05:11 UTCReport an error
Business address3940 TRUST WAY, HAYWARD, CA, 945452026-11-13SEC EDGAR company profile2026-11-22 05:11 UTCReport an error
ExchangesNasdaq2026-11-13SEC EDGAR company profile2026-11-22 05:11 UTCReport an error
Net income (loss) (fiscal year ended 2026-06-30)$-45,546,0002026-06-3010-K, XBRL NetIncomeLoss2026-11-22 05:11 UTCReport an error
Total assets (at 2026-06-30)$182,623,0002026-06-3010-K, XBRL Assets2026-11-22 05:11 UTCReport an error
Stockholders' equity (at 2026-06-30)$177,013,0002026-06-3010-K, XBRL StockholdersEquity2026-11-22 05:11 UTCReport an error
Cash and cash equivalents (at 2026-06-30)$179,972,0002026-06-3010-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 05:11 UTCReport an error
Operating cash flow (fiscal year ended 2026-06-30)$-16,518,0002026-06-3010-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 05:11 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2026-06-30)$105,0002026-06-3010-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 05:11 UTCReport an error
Operating lease liabilities (at 2026-06-30)$762,0002026-06-3010-K, XBRL OperatingLeaseLiability2026-11-22 05:11 UTCReport an error
Form D total offering amount (D filed 2024-04-25)$40,000,0182024-04-25D2026-11-22 05:11 UTCReport an error
Form D total amount sold (D filed 2024-04-25)$40,000,0182024-04-25D2026-11-22 05:11 UTCReport an error
Form D industry groupBiotechnology2024-04-25D2026-11-22 05:11 UTCReport an error
Form D revenue rangeDecline to Disclose2024-04-25D2026-11-22 05:11 UTCReport an error
Form D date of first sale2024-04-222024-04-25D2026-11-22 05:11 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-13)On November 13, 2026, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2026 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition…2026-11-13SEC EDGAR 8-K 0001193125-26-459339 (text as filed, excerpt)2026-11-22 05:11 UTCReport an error
8-K Item 5.03, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year (filed 2026-11-13)On November 12, 2026, the Board of Directors of the Company approved a resolution changing the Company’s fiscal year-end date from June 30 to December 31 of each calendar year, effective as of the same date. As a result, the Company will report operating results covering the six-month transition period from July 1, 2026 through December 31, 2026 (the “Transition Period”) in a Transition Report on Form 10-K. Following the Transition Period, the Company will report its operating results on a calendar-year basis, beginning with the fiscal year commencing January 1, 2027 and ending December 31, 2027. Prior to the change in fiscal year end, the Company reported financial results on a fiscal-year…2026-11-13SEC EDGAR 8-K 0001193125-26-459339 (text as filed, excerpt)2026-11-22 05:11 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-28)On October 28, 2026, Benitec Biopharma Inc. (the “Company”) issued a press release providing an update to announce positive interim Phase 1b/2a results for high dose BB-301 and continued durable improvements for low dose BB-301. A copy of the press release, which is attached hereto as Exhibit 99.1, is furnished pursuant to this Item 7.01. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing of the Company, whether made before, on or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The…2026-10-28SEC EDGAR 8-K 0001193125-26-435159 (text as filed, excerpt)2026-11-22 05:11 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-05)On October 5, 2026, Benitec Biopharma Inc. (the “Company”) issued a press release providing an update following the receipt of formal feedback from the U.S. Food and Drug Administration ("FDA") related to the Type C meeting between the Company and the FDA in the third quarter of the 2026 calendar year. A copy of the press release, which is attached hereto as Exhibit 99.1, is furnished pursuant to this Item 7.01. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing of the Company, whether made before, on or after the date hereof, regardless of any general incorporation language in such…2026-10-05SEC EDGAR 8-K 0001193125-26-413177 (text as filed, excerpt)2026-11-22 05:11 UTCReport an error
8-K Item 4.01, Changes in Registrant’s Certifying Accountant (filed 2026-09-30)New Independent Registered Public Accounting Firm As previously disclosed on a Current Report on Form 8-K with the Securities and Exchange Commission that Benitec Biopharma Inc. (the “Company”) filed on September 24, 2026, the Company reported the approval of the engagement of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2027. The engagement was subject to EY completing its client acceptance process. On September 28, 2026, EY completed its client acceptance procedures. On September 29, 2026, the Company and EY executed an engagement letter to engage EY as the Company’s independent registered public accounting…2026-09-30SEC EDGAR 8-K 0001193125-26-409052 (text as filed, excerpt)2026-11-22 05:11 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.